Investing in Biotechnology

Jessica YuBiotech 2

Company Description (Week 0 – 7)

Genentech, Inc. (DNA)- Goals: Discovering, developing,

manufacturing, and commercializing biotherapeutics in the U.S.

- Products: Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarvceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme, Raptiva,

- Number of shares purchased: 7 shares- Price per share at purchase: $78.30

Genzyme Corp. (GENZ)- Located in the U.S. the European Union,

Latin America, and Asia Pacific- Consists of 5 specialized branches: Renal,

Therapeutics, Transplant, Biosurgery, and Genetics

- Products: Renagel, Hectoral vitamin D2 pre-hormone products, Cerezyme/Ceredase, Fabrazyme, Thyrogen, Myozyme, Aldurazyme, Thymoglobulin, Lymphoglobuline, Synvisc, Sepra products,

- Number of shares purchased:7 shares- Price per share at purchase: $64.07

Company Description (Week 8 - 15)

Questcor Pharmaceuticals, Inc. (QSC)

- Goals: Novel therapeutics for treating diseases and diseases of the central nervous system

- Products: H.P. Acthar Gel, Doral- Number of shares purchased: 500 shares- Price per share at purchase: $1.37

Sangamo Biosciences (SGMO)

- Goals: Researching and developing novel DNA-binding proteins for therapeutic gene regulation and modification

- Achievements: development of a class of DNA-binding proteins, called zinc finger DNA-binding proteints (ZFPs)

- Number of shares purchased: 19 shares- Price per share at purchase: $18.86

Events Affecting Company Stocks

Genentech, Inc. (-)- Alteration of a plan to discourage doctors from using Avastin to treat

eye disease because of FDA concerns, but it also may have damaged Lucentis sales by angering retina specialists

Genzyme Corporation (+)- the U.S. Food and Drug Administration has granted Epicel, its product

for the treatment of life-threatening wounds resulting from severe burns

Questcor Pharmaceuticals, Inc. (+)- U.S. shipments of its main product Acthar, a hormone used to treat

swelling and allergic reactions, increased by 4 percent in December from the previous month

Sangamo Biosciences (-)- Holder Kopp Investment Advisors cuts stake in Sangamo Biosciences

to 7.2 percent

Performance Graphs

Price Per Share over 16 Weeks

0

10

20

30

40

50

60

70

80

0 2 4 6 8 10 12 14 16

Time (Weeks)

Pri

ce p

er S

har

e ($

)

DNA

GENZ

QSC

SMGO

Price p

er S

hare

($)

*DNA was switched with QSC after week 7** GENZ was switched with SGMO after week 7

Total Stock Values for 16 Weeks

0

500

1000

1500

2000

2500

3000

0 2 4 6 8 10 12 14

Time (Weeks)

DNA (7 shares)QSC (500 shares)GENZ (7 shares)SGMO (19 shares)

*DNA was switched with QSC after week 7** GENZ was switched with SGMO after week 7T

ota

l Sto

ck Val

ue

($)

Stock Investment Summary

- Total Stock Value at Purchase: $996.59- Total Stock Value after 16 Weeks:

$3057.39- Net profit: $2060.80- Percent Increase from Original Stock

Value: +206.79%